BAY 59-8862 in Treating Patients With Advanced Kidney Cancer

Status unconfirmed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have advanced kidney cancer.

Key facts

Study ID

NCT00039169

Run by

Theradex

Starts

2001-12-01

Last updated by the study team

2008-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Scripps Clinic — La Jolla, California, United States
• Medical Consultants — Muncie, Indiana, United States
• Ochsner Clinic — New Orleans, Louisiana, United States
• Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• 206 Research Associates — Greenbelt, Maryland, United States
• St. Louis University Health Sciences Center — St Louis, Missouri, United States
• Billings Oncology Associates — Billings, Montana, United States
• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• State University of New York - Upstate Medical University — Syracuse, New York, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• Tom Baker Cancer Center - Calgary — Calgary, Alberta, Canada
• Cross Cancer Institute — Edmonton, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.